Senti Biosciences Holdings, Inc. SNTI
We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits. These gene circuits, which we created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. Using gene circuits, our product candidates are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $22.0K | $0 | $2.0M | $3.3M | $2.3M | — |
| R&D | $37.6M | $34.4M | $32.1M | $28.1M | $22.0M | — |
| SG&A | $26.2M | $26.4M | $37.2M | $38.2M | $21.2M | — |
| Total operating expenses | $68.8M | $61.0M | $95.3M | $66.4M | $43.2M | — |
| Operating income | -$68.8M | -$61.0M | -$92.7M | -$62.1M | -$40.4M | — |
| Pre-tax income | -$61.4M | -$52.8M | — | — | — | — |
| Income tax | $0 | $0 | — | — | — | — |
| Net income | -$61.4M | -$52.8M | -$71.1M | -$58.2M | -$55.3M | — |
| EPS, basic | -2.73 | -12.03 | -16.01 | -2.23 | -19.00 | — |
| EPS, diluted | -2.73 | -12.03 | -16.01 | -2.23 | -19.00 | — |
| Shares, diluted (wtd. avg.) | 22.5M | 4.6M | 4.4M | 26.1M | 2.9M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $16.4M | $48.3M | $39.4M | $61.0M | $59.3M | $31.0M |
| Short-term investments | — | — | $0 | $40.9M | $0 | — |
| Receivables | — | — | — | $626.0K | $483.0K | — |
| Total current assets | $23.3M | $59.0M | $71.2M | $102.6M | $60.2M | — |
| Property, plant and equipment | $12.9M | $21.3M | $25.3M | $51.4M | $12.4M | — |
| Total assets | $51.2M | $97.8M | $119.5M | $180.8M | $96.7M | — |
| Accounts payable | $2.9M | $1.5M | $1.2M | $1.4M | $5.2M | — |
| Total current liabilities | $14.0M | $13.1M | $12.7M | $18.1M | $14.5M | — |
| Total liabilities | $45.6M | $47.1M | $52.6M | $53.5M | $36.3M | — |
| Retained earnings | -$358.6M | -$297.1M | -$244.3M | -$173.3M | -$115.1M | — |
| Total equity | $5.6M | $25.6M | $66.9M | $127.3M | -$111.5M | -$58.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$43.4M | -$41.4M | -$52.4M | -$34.9M | -$34.6M | — |
| Depreciation and amortisation | $3.6M | $3.8M | $3.6M | $1.4M | $769.0K | — |
| Stock-based compensation | $5.7M | $1.8M | $9.7M | $16.4M | $2.3M | — |
| Capital expenditure | $196.0K | $26.0K | $12.0M | $41.4M | $5.5M | — |
| Investing cash flow | -$184.0K | $34.0K | $30.1M | -$82.0M | -$5.5M | — |
| Financing cash flow | $11.8M | $53.7M | $779.0K | $118.6M | $68.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028429.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $2.3M | $3.3M | $2.0M | $0 | $22.0K |
| Gross profit | — | — | — | — | — | — |
| Net income | — | -$55.3M | -$58.2M | -$71.1M | -$52.8M | -$61.4M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Material agreement signed Item 1.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Material agreement signed Item 1.01
- New debt or obligation Item 2.03
- Material agreement signed Item 1.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Change of control Control of the company has changed hands. Item 5.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |